This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Editas (EDIT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.
The Zacks Analyst Blog Highlights: Visa, Exxon Mobil, SAP, Union Pacific and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Exxon Mobil, SAP, Union Pacific and Gilead Sciences
Top Research Reports for Tesla, Visa & Exxon Mobil
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), Visa (V), and Exxon Mobil (XOM).
Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.
What's in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.
What's in Store for Emergent (EBS) This Earnings Season?
by Zacks Equity Research
On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.
Will Strong Veklury and HIV Sales Aid Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports first-quarter 2021 results.
Is a Beat in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche (RHHBY) Q1 Sales Affected by Biosimilars & COVID-19
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2021 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $66.38 in the latest trading session, marking a +0.65% move from the prior day.
Why Gilead (GILD) Could Beat Earnings Estimates Again
by Zacks Equity Research
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo
by Zacks Equity Research
Lilly (LLY) plans to stop COVID-19 treatment with bamlanivimab alone in the United States. Instead, a combination of bamlanivimab and etesevimab will be available for the same, a better therapy for variants.
Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.
Merck (MRK) Stops MK-7110 Development, Focuses on Molnupiravir
by Zacks Equity Research
Merck (MRK) will start evaluating oral molnupiravir in non-hospitalized COVID-19 patients in a late-stage study. It stops MK-7110 development due to requirement of additional studies.
Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $65.30, moving +0.63% from the previous trading session.
Gilead (GILD) Gets FDA Nod for Trodelvy in Urothelial Cancer
by Zacks Equity Research
The FDA grants accelerated approval to Gilead's (GILD) Trodelvy for treating adult patients with locally-advanced or metastatic urothelial cancer.
Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study
by Zacks Equity Research
Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy
by Zacks Equity Research
Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of Lilly (LLY)/Incyte's (INCY) label expansion application for Olumiant in atopic dermatitis by three months.